Complexa is a clinical-stage biopharmaceutical company based in Radnor, Pa., led by President and CEO Josh Tarnoff. The company is advancing CXA-10, an oral nitrated fatty acid (NFA) compound that upregulates Nrf2 and inhibits NF-κB to reduce inflammation and fibrosis. Complexa leverages a proprietary platform to develop endogenous NFAs to restore anti-inflammatory and tissue-repair pathways in diseases with high oxidative stress. Its lead program targets focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), with a Phase 2 trial of oral CXA-10 in FSGS expected to start in early 2018. The company completed a $62M Series C to fund clinical development of CXA-10 and to advance a second compound toward an IND for a yet-to-be-disclosed indication. Complexa is a clinical-stage, platform anti-inflammatory and fibrotic disease-focused biopharmaceutical company based in Pittsburgh, PA. Its proprietary technology centers on the synthesis and therapeutic application of endogenous nitro-fatty acids (NFAs) and related structure/function mediators. The company’s lead compound is CXA-10, being developed in two formulations: an intravenous formulation currently in Phase I for a form of acute kidney disease, and an oral formulation for a form of chronic kidney disease for which an IND will be filed later this year. Complexa is led by President and CEO Josh Tarnoff. The company will use proceeds from its recent financing to further advance clinical development of both CXA-10 formulations. No operating metrics were disclosed in the article. Complexa, founded in 2008 and based in Pittsburgh, develops nitrated unsaturated fatty acids to treat inflammatory and metabolic disorders. Its initial clinical focus is acute and chronic kidney disease, and its lead compound, CXA-10, is targeted at contrast imaging–induced nephropathy (CIN), a form of acute kidney injury. CIN can lead to extended hospitalization, dialysis, or death. The company also has several proprietary second‑generation drug candidates that are structurally distinct from CXA‑10 and are being developed to target significant inflammatory and metabolic conditions. These candidates are intended to facilitate future partnering opportunities. Financially, Complexa raised $200K in the reported financing, a follow‑on investment from Pittsburgh Life Sciences Greenhouse (PLSG). PLSG, managing member of the PLSG Accelerator Fund, has invested a total of $550,000 into the company.

Total raised

$75M

Funding rounds

3

Latest round

Series C

Latest activity

Jul 2017